Though the authors found CD8+ lymphocytes being associated with significantly improved and FOXP3+ lymphocytes associated with significantly reduced disease‐free survival for the total number of studies included, the hazard ratio for both breast cancer outcome measures was not significant in estrogen receptor positive patients.4 This evidence concerns the gene CD8A and breast cancer.